Best or Worst IdeaDay 12: All-In on an FDA Decision
Abandoned the dead money. Bet everything on Friday.
February 18, 2026 · Day 12 of 90
The Morning: Dead Money
Coming off Presidents' Day, I was ready to execute on the research from Day 11. The plan: buy IREN based on Congressman Cleo Fields' position and ride the momentum.
I entered IREN at $41.16 with full Williams/Kotegawa conviction — essentially all-in with 22 shares.
Then... nothing.
The stock drifted. It dropped to $39.50 (testing my stop), bounced back to $41.40, then just... sat there. No momentum. No conviction. Just Bitcoin-correlated noise.
After watching it chop around for hours, I made the call: cut the dead money.
The Pivot: Finding Real Catalyst
I asked Claude for something different. Not just "beaten down" or "momentum starting." I wanted:
- Low share price (load up on shares)
- Concrete catalyst within days
- Potential for a huge run
- No Bitcoin correlation
After researching SNAP (7-year lows), ACHR (eVTOL speculation), and others, Claude found it:
VNDA — Vanda Pharmaceuticals.
FDA decision on Bysanti (milsaperidone) for bipolar disorder and schizophrenia. Target date: February 21, 2026.
That's this Friday. Three days away.
Why VNDA?
| Factor | Detail |
|---|---|
| Catalyst | FDA decision Friday Feb 21 |
| Price at Entry | $6.07 (near daily low) |
| Market Opportunity | $20 billion antipsychotic market |
| Recent Track Record | NEREUS approved by FDA in December |
| Review Status | "No potential review issues identified" |
| Analyst Target | $11 (B. Riley) — 80% upside |
The FDA already approved Vanda's motion sickness drug in December. They have a track record of regulatory execution. And importantly — no Bitcoin correlation. This is pure biotech binary event trading.
Today's Trades
| Action | Ticker | Shares | Price | Total |
|---|---|---|---|---|
| SELL | IREN | 22 | ~$41 | ~$902 |
| BUY | VNDA | ~150 | $6.07 | ~$910 |
End of Day
VNDA closed at $6.22 — up +2.5% from my entry.
That's roughly $22-23 profit on day one of this position.
More importantly: I'm positioned for Friday.
Current Position
| Stock | Shares | Entry | Current | P/L |
|---|---|---|---|---|
| VNDA | ~152 | $6.07 | $6.22 | +2.5% |
The Binary Bet
Let me be clear about what this trade is:
If the FDA approves Bysanti: VNDA could rip 50-100%+. The stock ran 62% from November to December on FDA optimism alone.
If the FDA rejects: The stock tanks 30-50%. There's no stop loss that saves you from a gap down.
This is gambling with an edge. The "edge" is:
- FDA identified no review issues
- Vanda just got another drug approved
- The science is solid (bioequivalent to existing approved drug)
- $20B market opportunity
But it's still a coin flip with asymmetric outcomes. Classic biotech FDA play.
The Scoreboard
| Metric | Value |
|---|---|
| Starting Capital | $1,000 |
| Current Value | ~$935 |
| Total Return | -6.5% |
| Day | 12 of 90 |
| Next Catalyst | Feb 21 — FDA Decision |
Trade Record
| Trade | Result | Return |
|---|---|---|
| VNDA (initial) | Loss | -4.3% |
| IREN (earnings) | Win | +4.8% |
| AMKR | Win | +2.8% |
| HOOD | Loss | -11.8% |
| SHOP | Breakeven | ~0% |
| RIVN | Win | +6.0% |
| IREN (day 12) | Breakeven | ~0% |
Record: 3 wins, 2 losses, 2 breakeven
What's Next
Three days. That's it.
Wednesday and Thursday will be positioning days — watching for any pre-announcement movement, unusual options activity, or leaks.
Friday is judgment day.
Either this experiment gets a massive boost, or we take a hit and regroup. That's the game we're playing now.
See you tomorrow.
Disclaimer: This is a personal experiment for entertainment and educational purposes, not financial advice. Trading stocks involves significant risk — you can lose some or all of your money. Binary FDA events are extremely high-risk. I am not a licensed financial advisor. Do your own research before making any investment decisions. Past performance does not guarantee future results. If you sign up for Robinhood using my link, I may receive a referral bonus at no cost to you.